Healthcare

IDT Australia Limited (ASX:IDT) has reported its FY2026 results, highlighting revenue growth across its manufacturing divisions, a reduction in EBITDA losses, and a strategic focus on improving profitability while expanding manufacturing capabilities.

Telix Pharmaceuticals (ASX:TLX) delivered revenue of US$477 million for the six months ended 30 June 2026, representing a 22% increase from US$390 million in H1 2025. Its shares were trading at $17.10 on 20 August 2026, up 26 cents, or 1.54%, at 11:29 am.

EBOS Group (ASX:EBO) reportedRevenueof A$13.5 billion for the year to 30 June 2026, up 9.9 per cent. Underlying EBITDA rose 5.0 per cent to A$614 million. Underlying net profit after tax slipped 3.1 per cent to A$250 million, weighed down by theDepreciationand financing costs …

Reporting for the year to 30 June 2026, Healius lifted underlyingRevenue2.1 per cent to $1,373.2 million and underlying EBITDA 8.1 per cent to $258.6 million. The standout was the pace of margin recovery: pathology EBITDA margin rose 80 basis points to 18.6 per cent, …

Cash context matters here. Earlier in the year, Cochlear (ASX:COH) stunned the market by cutting FY26 underlying net profit guidance from $435-460 million to $290-330 million, blaming softer-than-expected implantDemandin developed markets since the start of the year and heightened uncertainty over Middle East sales …

For the 12 months to 30 June 2026, CSL reportedRevenueof US$15.8 billion, down 1 per cent in constant currency, and underlying NPATA of US$3.1 billion, down 2 per cent. The statutory swing to a loss — from a US$3.0 billion profit in FY25 — …

Over a ten-week stretch between late spring and early August, 4DMedical fired off announcement after announcement. Earlier in the run it signed a three-year commercial agreement with SimonMed Imaging, one of the largest US outpatient radiology networks, to deploy its CT:VQ and LDAf software …